Speaker Profile

Ph.D., Director Clinical Affair and Partnerships, Claret Bioscience

Dr. Varsha Rao is the Director of Clinical Affairs and Partnerships at ClaretBio where she oversees clinical application of the innovative NGS tools developed at ClaretBio in a variety of liquid biopsy-based diagnostic studies. Prior to her current role, Dr. Rao was a scientist at Prof. Michael Snyder’s lab at Stanford University where she lead projects that integrated cell and cell-free transcriptomic data in the context of metabolic diseases, viral infections, myelodysplastic syndrome and the NASA Twin Study. She received her Ph.D from the University of Maryland Baltimore County (2012) where she worked on identifying novel protein degradation mechanisms underlying prostate cancer progression.

Clinical Dx Showcase:
Claret Bioscience

Claret Bioscience LLC, builds NGS tools to enhance the quality of data obtained from highly degraded, low yield samples such as liquid biopsy and FFPE. Their technologies capture extremely fragmented DNA and retain native DNA termini information enabling accurate disease profiling using DNA fragmentomics.

Specialized NGS approach for improved diagnoses from highly degraded clinical samples
ClaretBio’s NGS approach SRSLY® provides the best data from the worst clinical samples. By capturing damaged, nicked, single-stranded, short fragments, and native termini from cell-free and FFPE DNA, more complex libraries and precise genomic origin are captured enabling accurate diagnoses.

 Session Abstract – PMWC 2022 Silicon Valley

Track 6 - June 28 9.00 A.M.-4.45 P.M.,Track 6 - June 29 3.30 P.M.-3.45 P.M.,Track 6 - June 30 9.00 A.M.-1.15 P.M.

The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative


Add Names/PO on Receipt

Apply to Speak at PMWC Silicon Valley by NOV. 30TH

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.

Contact Us:

Fields marked with an * are required 

Contact Us:

Fields marked with an * are required 

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts

Contact Us:

Fields marked with an * are required 

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required